Semax is a synthetic seven-amino-acid peptide derived from ACTH that is approved in Russia and Ukraine for cognitive enhancement and stroke recovery, primarily by boosting brain-derived growth factors and modulating dopamine and serotonin signaling.
What it does
Semax is built from the 4–7 fragment of ACTH (adrenocorticotropic hormone, the pituitary signal that normally tells the adrenal glands to release cortisol), but with a Pro-Gly-Pro tail added to improve stability. Crucially, the part of ACTH that stimulates cortisol release sits in positions 1–3, not 4–7 — so Semax produces no adrenal activation and no cortisol spike. Its cognitive effects come from a different mechanism entirely Yu 2021.
The clearest mechanism is upregulation of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) — proteins that support the growth, survival, and plasticity of neurons — particularly in the hippocampus and cortex. Higher BDNF levels are associated with better learning and memory consolidation, and Semax reliably raises them in animal models B 2024 B 2021. It also shifts intracellular calcium dynamics in brain neurons in ways consistent with neuroprotection N 2025.
Semax additionally modulates dopaminergic and serotonergic neurotransmission (the systems that govern attention, motivation, and mood), which likely explains reported improvements in focus and information-processing speed without the jitteriness of classical stimulants S 2024. In stroke and ischemia models, it reduces infarct volume (the area of dead tissue) by activating anti-apoptotic gene programs — pathways that prevent neurons from undergoing programmed cell death — and appears to influence immune gene expression in the early post-stroke period Yu 2021 B 2023 B 2025.
What the evidence shows
Stroke recovery and neuroprotection Moderate rodent evidence; limited but clinically relevant human data (basis for Russian regulatory approval)
In rat cerebral ischemia-reperfusion models, Semax consistently reduces infarct size and improves functional recovery. Proteomics and transcriptomics confirm it shifts gene expression in ischemic brain regions toward survival and anti-apoptotic programs Yu 2021 B 2025 B 2023. An anti-inflammatory effect — including modulation of IL-4, IL-10, and IL-13 (cytokines that regulate immune response) — has also been documented in spinal cord injury models Asadullah 2023. These findings form the mechanistic foundation for its Russian approval for acute stroke and stroke rehabilitation, though large Western randomized controlled trials are absent.
Cognitive enhancement and nootropic use Solid mechanistic and rodent data; human evidence largely anecdotal or from small Russian-language trials
Semax reliably elevates BDNF and NGF in hippocampal and cortical tissue in rodents, which in turn supports synaptic plasticity and memory formation B 2024 B 2021. Calcium signaling studies in rat neurons show it alters intracellular dynamics in a manner consistent with enhanced neuronal excitability and communication N 2025. Self-reported human experience — widely documented across Russian-language medical literature and international nootropic communities — describes improved working memory, attention, and mental stamina, but these reports are not a substitute for blinded trials.
Mood and stress resilience Rodent evidence; no controlled human trials identified
In a chronic unpredictable stress rat model, Semax produced antidepressant-like and antistress effects comparable to Melanotan II, likely via serotonergic and melanocortin pathways S 2024. Hippocampal gene expression studies confirm it corrects stress-induced transcriptomic disruptions in male rats B 2021. Semax also appears to interact with the GABA receptor system — the primary inhibitory neurotransmitter system — producing both acute and delayed modulatory effects that could contribute to anxiolytic activity V 2023. Human data here is essentially absent.
Alzheimer's / amyloid pathology Early in vitro evidence only
One in vitro study found Semax interferes with copper-induced aggregation of amyloid-beta (the protein fragment that accumulates in Alzheimer's disease plaques) in artificial membrane models M 2022. This is a mechanistically interesting finding but extremely early-stage — no animal efficacy data, no human data.
How it's used
In studies and self-reported protocols, intranasal administration is by far the most common route, using pharmaceutical-grade solution delivered directly to the nasal mucosa. Doses in clinical and research contexts range from 200 mcg twice daily for general cognitive use, up to 600–900 mcg two to three times daily for more intensive neurological applications, and as high as 1,500 mcg intranasally in acute stroke settings. Subcutaneous injection is occasionally reported but less common. Half-life is approximately 30 minutes, though users and some researchers report subjective effects lasting several hours. Timing in self-reported protocols typically follows a morning and mid-day schedule to avoid sleep interference.
Side effects and safety
Reported side effects are generally mild. Nasal dryness and mild headache are the most common complaints with intranasal use. At higher doses or in sensitive individuals, irritability, insomnia, and blood pressure fluctuations have been reported. Psychomotor agitation — restlessness and heightened arousal to a disruptive degree — appears rarely but is documented. Absolute contraindications in clinical use include pregnancy and a history of psychosis. Epilepsy and severe anxiety are relative contraindications, given a theoretical possibility that pro-excitatory neurological effects could lower seizure threshold or amplify anxiety. Long-term safety data in humans is essentially nonexistent outside Russian clinical practice; the duration and frequency of use in those settings is not well characterized in English-language literature.
Bottom line
Semax has a well-supported mechanistic rationale — BDNF upregulation, neuroprotection in ischemia models, and dopamine/serotonin modulation — backed by a substantial body of rodent research and decades of Russian clinical use Yu 2021 B 2024 S 2024. What it lacks is rigorous Western trial data: no large randomized controlled trials, no long-term safety studies in Western populations. It's a reasonable area of interest for someone researching cognitive support or neuroprotection, but the evidence base requires honest calibration.